- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Prevention and treatment of deep vein thrombosis; haemodialysis
- Meeting Date: July 2020
- Public Summary Document (PSD) July 2020 PBAC Meeting - (PDF 924KB)
- Public Summary Document (PSD) July 2020 PBAC Meeting - (Word 58KB)
Enoxaparin – July 2020
Enoxaparin: Injection containing enoxaparin sodium 100 mg (10,000 I.U. anti-Xa) in 1 mL pre-filled syringe, Injection containing enoxaparin sodium 120 mg (12,000 I.U. anti-Xa) in 0.8 mL syringe, Injection containing enoxaparin sodium 150 mg (15,000 I.U. anti-Xa) in 1 mL syringe, Injection containing enoxaparin sodium 20 mg (2,000 I.U. anti-Xa) in 0.2 mL pre-filled syringe, Injection containing enoxaparin sodium 40 mg (4,000 I.U. anti-Xa) in 0.4 mL pre-filled syringe, Injection containing enoxaparin sodium 60 mg (6,000 I.U. anti-Xa) in 0.6 mL pre-filled syringe, Injection containing enoxaparin sodium 80 mg (8,000 I.U. anti-Xa) in 0.8 mL syringe; Enoxapo®
